Language Selection

Get healthy now with MedBeds!
Click here to book your session

Protect your whole family with Orgo-Life® Quantum MedBed Energy Technology® devices.

Advertising by Adpathway

         

 Advertising by Adpathway

Chemotherapy Stresses Mast Cells to Impair Immune Niches in Brain Metastases

1 day ago 19

PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY

Orgo-Life the new way to the future

  Advertising by Adpathway

Chemotherapy administered before surgical resection for lung cancer brain metastasis triggers a localized tissue-stress response that activates mast cells and curtails the structural maturation of tertiary lymphoid structures within intracranial tumors, according to a multimodal translational study published in the Journal of Hematology & Oncology. Brain metastases from lung cancer represent a lethal and frequent manifestation of advanced malignancy, accounting for approximately half of all systemic cancer spreads to the central nervous system in contemporary cohorts. While tertiary lymphoid structures—organized ectopic aggregates of lymphocytes that support local antitumor immunity—correlate with favorable survival outcomes across multiple solid malignancies, the biological processes governing whether these niches mature or arrest during cytotoxic treatment have remained poorly defined. By evaluating clinical cohorts, bulk and single-cell transcriptomic profiles, high-plex spatial imaging, and intracranial murine models, researchers identified an alarmin-driven signaling circuit in which chemotherapy prompts tumor cells to release interleukin-33, recruiting and degranulating mast cells that suppress adaptive antitumor responses through prostaglandin D2.

Tertiary lymphoid structures function as specialized regional hubs where T cells and B cells organize into functional compartments capable of orchestrating sustained adaptive immune attacks against malignant tissue. Within primary and metastatic tumors, fully mature lymphoid aggregates develop germinal center-like characteristics, marked by proliferating B lymphocytes, active follicular dendritic cell networks, and terminal differentiation of plasma cells producing tumor-directed antibodies. In contrast, immature aggregates typically exhibit loose, disorganized lymphocytic infiltration without clear compartmentalization, providing inconsistent or negligible clinical benefit. Although recent therapeutic advances combining cytotoxic chemotherapy with immune checkpoint inhibitors have shown measurable intracranial activity in non-small cell lung cancer brain metastases, cytotoxic agents also introduce intense cellular injury and inflammation. Cellular damage caused by chemotherapeutic drugs frequently mobilizes counter-regulatory programs, including checkpoint ligands, immunosuppressive myeloid cells, and tissue-protective alarmins that can paradoxically dampen effector lymphocyte function and arrest organized immune architecture.

To establish the clinical relevance of lymphoid maturation in intracranial disease, the investigators examined a cohort of 130 patients undergoing surgical resection for lung cancer brain metastasis at Huashan Hospital, Fudan University. Histopathological and multiplex immunofluorescence analyses categorized tumors into tertiary lymphoid structure-negative, immature, and mature states based on lymphoid aggregation and cellular organization. Among 126 patients with evaluable longitudinal follow-up, those harboring mature tertiary lymphoid structures achieved significantly longer overall survival following intracranial resection compared to patients whose tumors contained immature structures (P = 0.005). Mature formations displayed prominent T-cell and B-cell compartmentalization along with elevated proportions of Ki67-positive proliferating B cells (P = 0.007 compared to immature structures; P = 0.022 compared to structure-negative regions) and increased CD23-positive follicular networks (P = 0.042). In contrast, patient survival did not differ significantly between mature formations and lymphoid-negative tumors (P = 0.073) or between immature formations and lymphoid-negative lesions (P = 0.158), demonstrating that structural maturation, rather than mere lymphocytic presence, dictates clinical prognosis.

The study subsequently evaluated whether prior systemic oncological therapies influenced the structural development of these intracranial immune niches. Using multivariable logistic regression modeling that adjusted for cranial radiotherapy, targeted molecular therapies, immune checkpoint inhibitors, patient age, sex, and synchronous versus metachronous metastatic timing, preoperative chemotherapy emerged as an independent predictor of impaired lymphoid maturation. Specifically, prior chemotherapy exposure was associated with more than a ninefold increase in the odds of presenting with immature tertiary lymphoid structures (odds ratio = 9.17, 95% confidence interval 2.69 to 36.3; P = 0.0003). In contrast, cranial radiotherapy, molecular targeted therapy, and immune checkpoint inhibition exhibited no statistically significant associations with lymphoid maturation status. Consistent transcriptomic analyses across bulk and single-cell cohorts confirmed that tumors exposed to preoperative chemotherapy displayed lower overall lymphoid maturation signature scores alongside altered leukocyte composition, including shifts in memory B cells and effector memory T cells.

Seeking the biological drivers linking cytotoxic drug exposure to lymphoid arrest, the research team analyzed cytokine and inflammatory mediator profiles in fresh-frozen tumor specimens and transcriptomic libraries. Differential expression profiling identified the nuclear alarmin interleukin-33 as selectively enriched in chemotherapy-treated brain metastases and immature lymphoid niches. Multiplex cytokine profiling and enzyme-linked immunosorbent assays confirmed significantly higher interleukin-33 protein concentrations in homogenized chemotherapy-treated human tumors (n = 9) compared with treatment-naïve lesions (n = 13, P = 0.030). High-resolution spatial transcriptomics utilizing the Xenium platform determined that malignant epithelial cells accounted for 75.9 percent of all detected interleukin-33 transcripts, with smaller contributions from oligodendrocytes (9.6 percent) and pericytes (8.2 percent). In complementary in vitro experiments, exposing human lung cancer cell lines PC9 and H1975 to paclitaxel triggered substantial increases in interleukin-33 secretion, verifying that chemotherapeutic stress directly induces tumor cells to release this alarmin into the surrounding microenvironment.

Interrogation of single-cell transcriptomic datasets demonstrated that IL1RL1, the gene encoding the interleukin-33 receptor ST2, was selectively and predominantly transcribed by tumor-infiltrating mast cells rather than adjacent lymphoid or myeloid populations. When human mast-cell lines HMC-1 and LUVA were stimulated with recombinant interleukin-33, the cytokine induced robust, dose-dependent phosphorylation of canonical nuclear factor-kappa B signaling components, including p65 and IκBα. Cleavage under targets and tagmentation (CUT&Tag) profiling demonstrated that interleukin-33 stimulation dramatically enhanced genome-wide chromatin binding of phosphorylated p65 across gene bodies and regulatory regions of inflammatory loci. Furthermore, transcriptomic profiling of stimulated mast cells revealed extensive upregulation of inflammatory genes, including TNF, NLRP3, and NFKBIZ, alongside gene modules governing degranulation, granule biosynthesis, and immune-cell communication. Single-cell pseudotime trajectories constructed from human brain metastasis specimens mirrored this progression, tracing mast cells from a quiescent, antigen-presenting state toward an inflammatory and degranulating phenotype characterized by immediate-early transcription factors.

To evaluate whether this activated phenotype resulted in physical granule release within patients, researchers conducted ultrastructural and histological assessments of clinical specimens. Transmission electron microscopy of human metastatic tissue revealed prominent granule dissolution, cytoplasmic vacuolization, and extracellular granule extrusion in mast cells from chemotherapy-treated patients, contrasting sharply with the dense, intact granules seen in treatment-naïve specimens. Quantitative toluidine-blue histochemical staining confirmed that chemotherapy-exposed lesions harbored a significantly higher density of morphologically degranulated mast cells per high-power field than untreated lesions (P = 0.037), while counts of intact, non-degranulated mast cells remained comparable between groups (P = 0.487). Spatial transcriptomic and high-plex immunofluorescence analyses showed that while mast cells in treatment-naïve tumors were sparse and anatomically dissociated from lymphoid structures, chemotherapy-treated tumors exhibited striking spatial convergence: activated CD117-positive mast cells preferentially accumulated along the immediate borders and perivascular interfaces of CD3E-positive T-cell and CD20-positive B-cell aggregates.

The physical proximity of degranulated mast cells to lymphoid niches prompted investigators to screen mast-cell-derived secretory mediators for regulatory activity against lymphocytes. Primary murine splenic T cells and B cells were exposed in vitro to candidate mediators, including histamine, adenosine, and prostaglandin D2. While histamine and adenosine exerted modest effects, prostaglandin D2 (1 micromolar) triggered pronounced immunosuppressive transcriptional reprogramming. In T cells, prostaglandin D2 downregulated key cytotoxic effector and activation genes, including Gzma and Nkg7, while upregulating transcriptional markers of cellular stress and exhaustion such as Jun and Tox. In B-cell cultures, prostaglandin D2 suppressed gene networks critical for B-cell identity, antigen presentation, and immunoglobulin synthesis. In functional assays, prostaglandin D2 significantly impaired the ability of antigen-primed OT-I CD8-positive T cells to kill ovalbumin-expressing LLC-BM tumor cells (P = 0.022) without reducing baseline tumor viability, and markedly suppressed CD4-dependent CD138-positive plasma-cell differentiation in OT-II co-culture systems (P = 0.001).

Because prostaglandin D2 synthesis depends on hematopoietic prostaglandin D synthase (H-PGDS), the researchers tested whether pharmacologically blocking this pathway could restore chemotherapy efficacy in vivo. In immunocompetent C57BL/6J mice bearing intracranial LLC-BM tumors, animals were treated with vehicle, the small-molecule H-PGDS inhibitor GSK-2894631A administered orally twice daily, cytotoxic chemotherapy, or a combination of chemotherapy and GSK-2894631A. Serial bioluminescence imaging demonstrated that co-administering the H-PGDS inhibitor with chemotherapy achieved the greatest suppression of intracranial tumor expansion over time. Kaplan–Meier analysis demonstrated that mice receiving the combination therapy survived significantly longer than control animals and those receiving chemotherapy alone, achieving a median overall survival of 27 days compared to 22 days for vehicle control (P = 0.006) and 23 days for chemotherapy monotherapy (P = 0.029, with six mice per treatment group), demonstrating that intercepting downstream lipid mediators enhances cytotoxic tumor control.

To directly assess the therapeutic potential of halting mast-cell degranulation at its source, the team treated intracranial LLC-BM-bearing mice with cromolyn sodium, a clinically established mast-cell membrane stabilizer. Mice receiving cromolyn sodium (20 milligrams per kilogram intraperitoneally every two days) in combination with cytotoxic chemotherapy demonstrated significant reductions in intracranial tumor burden on bioluminescence imaging and achieved an extended median survival of 34.5 days, compared to 28.5 days for chemotherapy alone and 23.0 days for vehicle controls (log-rank P = 0.006; n = 6 per group). Histological analysis showed that adding cromolyn sodium significantly curtailed the abundance of morphologically degranulated mast cells in tumor tissue relative to chemotherapy alone (P = 0.046). Flow cytometry and immunohistochemistry demonstrated that combination therapy markedly remodeled the intracranial immune microenvironment, increasing intratumoral CD3E-positive T-cell (P = 0.016) and CD20-positive B-cell infiltration (P = 0.002), expanding the CD138-positive plasma-cell compartment, and reducing flow-cytometry-defined exhausted T cells.

The authors emphasized several methodological and biological caveats when interpreting their conclusions. The clinical observations were derived from retrospective, cross-sectional surgical cohorts in which patients underwent craniotomy, representing a selected subset of brain metastasis cases. Furthermore, many patients received concurrent cranial irradiation, and detailed information regarding specific chemotherapy regimens, cumulative cycles, and exact treatment-to-surgery intervals was unavailable, leaving open the potential for residual confounding or direct lymphotoxic effects. In experimental systems, the murine LLC-BM intracranial model does not develop the complex, highly compartmentalized tertiary lymphoid structure architecture observed in human patients, meaning that murine cellular shifts represent changes in localized adaptive immunity rather than de novo tertiary lymphoid organogenesis. Additionally, the in vitro functional assays utilized a supraphysiological concentration of prostaglandin D2, and cromolyn sodium can exert mast-cell-independent actions. Nonetheless, the findings delineate an alarmin-driven mast-cell checkpoint that curtails adaptive antitumor immunity during cytotoxic therapy, offering a mechanistic rationale for combining mast-cell stabilization with standard chemotherapy in brain metastasis.

Subject of Research: Mechanism of chemotherapy-induced mast-cell degranulation restraining tertiary lymphoid maturation in lung cancer brain metastasis

Article Title: Chemotherapy-induced mast-cell degranulation constrains tertiary lymphoid maturation in lung cancer brain metastasis

Article References: Fu, M., You, M., Ao, Y., Zeng, G., Xing, Y., Qiu, F., Zhang, L., Shen, Z., Hua, W., & Mao, Y. (2026). Chemotherapy-induced mast-cell degranulation constrains tertiary lymphoid maturation in lung cancer brain metastasis. Journal of Hematology & Oncology, 19(1), Article 103. https://doi.org/10.1186/s13045-026-01869-5

Image Credits: AI Generated

DOI: 10.1186/s13045-026-01869-5

Keywords: lung cancer brain metastasis, tertiary lymphoid structures, mast cells, chemotherapy, interleukin-33, prostaglandin D2, cromolyn sodium, H-PGDS, tumor microenvironment, adaptive immunity, plasma-cell differentiation, CD8+ T-cell cytotoxicity, ST2 receptor, NF-kappaB signaling, spatial transcriptomics, degranulation

Read Entire Article

         

        

Start the new Vibrations with a Medbed Franchise today!  

Protect your whole family with Quantum Orgo-Life® devices

  Advertising by Adpathway